Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab

This cohort study assesses the clinicopathological features, outcomes, and adverse events of older patients with metastatic colorectal adenocarcinomas.

[1]  F. Sinicrope,et al.  Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Youngchul Kim,et al.  A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. , 2022, European journal of cancer.

[3]  P. Gibbs,et al.  Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. , 2022, The Lancet. Oncology.

[4]  E. Van Cutsem,et al.  First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Fakih,et al.  Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases , 2021, JAMA network open.

[6]  P. Gibbs,et al.  Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). , 2021 .

[7]  L. Fashoyin-Aje,et al.  FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma , 2021, Clinical Cancer Research.

[8]  A. Chinnaiyan,et al.  Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination , 2021, Nature Medicine.

[9]  P. Gibbs,et al.  Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. , 2020, The New England journal of medicine.

[10]  J. Bluestone,et al.  Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis , 2020, Science Immunology.

[11]  S. Nomura,et al.  Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Jäger,et al.  Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Feiran Wang,et al.  Correlation between patients’ age and cancer immunotherapy efficacy , 2019, Oncoimmunology.

[14]  Stephen M. Douglass,et al.  Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations , 2018, Clinical Cancer Research.

[15]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[17]  A. Duval,et al.  Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. , 2017, European journal of cancer.

[18]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[19]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[20]  D. Sargent,et al.  Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers: A Secondary Analysis of 2 Randomized Clinical Trials , 2017, JAMA oncology.

[21]  C. Tournigand,et al.  Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. , 2016, The Lancet. Oncology.

[22]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[23]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[24]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[25]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[26]  Z. Tian,et al.  The liver works as a school to educate regulatory immune cells , 2013, Cellular and Molecular Immunology.

[27]  A. Hauschild,et al.  Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[29]  A. Spurdle,et al.  Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification , 2012, Journal of Medical Genetics.

[30]  P. Gibbs,et al.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.

[31]  J. Horiot,et al.  Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Peter W. Laird,et al.  Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening , 2008, Cancer Epidemiology Biomarkers & Prevention.

[33]  M. Kloor,et al.  Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. , 2008, Gastroenterology.

[34]  L. Baider,et al.  The illness trajectory of elderly cancer patients across cultures: SIOG position paper. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Hiroyuki Yamamoto,et al.  BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes , 2005, Oncogene.

[36]  H. Cohen,et al.  Never too old? Age should not be a barrier to enrollment in cancer clinical trials. , 2005, The oncologist.

[37]  M. Aapro,et al.  Adjuvant chemotherapy in the elderly. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  B. Vogelstein,et al.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. , 1994, The American journal of pathology.

[39]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[40]  D. Sargent,et al.  Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. , 2015, Gastroenterology.

[41]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.

[42]  B. Thiers.  Generalizability of Cancer Clinical Trial Results: Prognostic Differences between Participants and NonparticipantsElting LS, Cooksley C, Bekele BN, et al (Univ of Texas, Houston) Cancer 106:2452–2458, 2006§ , 2007 .

[43]  D.,et al.  Regression Models and Life-Tables , 2022 .